Fziomed, Inc. appears in FDA records as the applicant for Dynavisc under K262343, a traditional 510(k) with a substantially equivalent decision dated October 28, 2026. The submission was received July 10, 2026, and the clearance letter lists Dynavisc under 21 CFR 878.3300, surgical mesh, Class II, product code OWW. The company's own materials describe Dynavisc as an absorbable, clear, viscoelastic gel placed around tendon and peripheral nerve tissues during surgery. [1][2][5]
The K262343 submission and its scope
K262343 was received July 10, 2026, and decided October 28, 2026, as substantially equivalent, with a summary statement and no third-party review. The FDA letter identifies the trade name Dynavisc, regulation number 21 CFR 878.3300, regulation name surgical mesh, Class II, product code OWW, and the review advisory committee as general and plastic surgery. The applicant of record is Fziomed, Inc., 231 Bonetti Dr., San Luis Obispo, California. [1][2]
The clearance letter states that the intended use and key technological characteristics of the Dynavisc Tendon Protector are substantially equivalent to the VersaCoat (K251655) predicate device, and that differences were determined to be minor and did not raise different questions of safety or effectiveness. The non-clinical data provided was described as supporting substantial equivalence. [2]
Product form and stated mechanism
Fziomed's instructions for use describe Dynavisc as an absorbable, clear, viscoelastic gel applied during tendon and peripheral nerve surgery, supplied as a 1 mL luer-lock syringe with an applicator tip and instructions for use. The same document lists potential adverse events associated with tendon and peripheral nerve surgery performed without Dynavisc, and notes wound rupture among adverse events reported but not necessarily attributable to the product. [5]
Company product pages state that Dynavisc provides a temporary, protective separation of tissues adjacent to the surgical site during healing, and that it is formulated for tendon and peripheral nerve procedures including flexor tendon repair, tenolysis, Dupuytren's contracture, neurolysis and carpal tunnel syndrome. These are company statements about intended use and mechanism, not independently verified clinical findings. [3][8]
Company platform and product family
Fziomed describes itself as developing and manufacturing absorbable gel products based on a proprietary dual-polymer technology, with applications across surgical areas; the company states its products are made in the USA. Its product page names Oxiplex for spine surgery as an absorbable gel that coats and protects nerves and surrounding tissues. [6]
Trademarks listed as owned by Fziomed, Inc. and registered in the United States and certain foreign jurisdictions include FZIOMED, OXIPLEX, OXIPLEX/SP, DYNAVISC, INTERPOSE, INTERCOAT, OXIPLEX/AP and OXIPLEX/IU. The instructions for use name FzioMed, Inc. of San Luis Obispo as manufacturer and list FzioMed Australia Pty Ltd, OBELIS S.A and MedEnvoy Switzerland as associated entities. [5][6]
What the supplied filings do and do not establish
The supplied portfolio snapshot contains one linked 510(k) record, K262343, with a single SESE decision; that count reflects the retrieved filings as of the snapshot date and is not a measure of total company portfolio, sales or safety performance. A separate establishment listing record shows Dynavisc under product code OZJ, classification name inhibitor, postoperative fibrosis (adhesion barrier), device class not classified, which differs from the OWW classification in the K262343 record. [1][7]
An establishment registration search returns FZIOMED, INC. of CA/USA with registration number 2031637 for 2026. Ownership, parentage, headquarters beyond the addresses in the cited documents, customers and commercial availability are not established by the public documents. [9]


